iCAD, Inc. (NASDAQ:ICAD - Get Free Report)'s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.64 and traded as high as $3.85. iCAD shares last traded at $3.76, with a volume of 300,078 shares changing hands.
Analysts Set New Price Targets
Several equities research analysts have issued reports on ICAD shares. Laidlaw reissued a "hold" rating on shares of iCAD in a report on Thursday, April 17th. BTIG Research lowered shares of iCAD from a "buy" rating to a "neutral" rating in a report on Wednesday, April 16th. Wall Street Zen initiated coverage on shares of iCAD in a report on Tuesday, May 20th. They issued a "sell" rating on the stock. Finally, Craig Hallum lowered shares of iCAD from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 16th.
View Our Latest Analysis on ICAD
iCAD Trading Up 4.1%
The company's fifty day moving average price is $3.41 and its two-hundred day moving average price is $2.69. The firm has a market cap of $105.21 million, a P/E ratio of -29.46 and a beta of 1.38.
iCAD (NASDAQ:ICAD - Get Free Report) last posted its earnings results on Tuesday, May 13th. The technology company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.04. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%. The business had revenue of $4.87 million for the quarter, compared to analyst estimates of $4.54 million.
Institutional Investors Weigh In On iCAD
Hedge funds have recently added to or reduced their stakes in the stock. Thompson Davis & CO. Inc. bought a new stake in iCAD during the 4th quarter worth about $31,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in iCAD during the 1st quarter worth about $40,000. Goldman Sachs Group Inc. bought a new stake in iCAD during the 1st quarter worth about $44,000. PKS Advisory Services LLC bought a new stake in iCAD during the 4th quarter worth about $53,000. Finally, Cubist Systematic Strategies LLC bought a new stake in iCAD during the 1st quarter worth about $71,000. Institutional investors own 24.61% of the company's stock.
About iCAD
(
Get Free Report)
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
Featured Articles
Before you consider iCAD, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iCAD wasn't on the list.
While iCAD currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
